Triflusal Triflusal Triflusal is a platelet aggregation inhibitor that was discovered and developed in the Uriach Laboratories, and commercialised in Spain since 1981. Currently, it is available in 25 countries in Europe, Asia, Africa and America. It is a drug of the salicylate family but it is not a derivative of acetylsalicylic acid (ASA). Trade names include Disgren, Grendis, Aflen and Triflux. Triflusal is a selective platelet antiaggregant through; Triflusal is indicated for; In the 2008 guidelines for stroke management from the European Stroke Organization, triflusal was for the first time recommended as lone therapy, as an alternative to acetylsalicylic acid
Sterling Drug Sterling Drug Sterling Drug was an American global pharmaceutical company, known as Sterling-Winthrop, Inc. after the merger with Winthrop-Stearns Inc. (which resulted from the merger of "Winthrop Chemical Company Inc." and "Frederick Stearns & Company"). It was formerly known as "Sterling Winthrop Pharmaceuticals", whose primary product lines included diagnostic imaging agents, hormonal products, cardiovascular products, analgesics, antihistamines and muscle relaxants. Chemical compounds produced by this company were often known by their manufacturing code which consisted of the abbreviation WIN (for Winthrop) followed by a number. For example, WIN 18,320 was nalidixic acid, the first quinolone antibiotic. The Company was established